{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T12:29:19Z","timestamp":1780748959911,"version":"3.54.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In recent years, several threatening developments regarding antibacterial drugs, such as rising bacterial resistance and delivery bottlenecks, have occurred. Since antibacterial drugs are crucial for modern medicine, understanding events and influencing factors relevant for long-term developments is essential. Therefore, we analyzed the number of prescriptions and costs, defined daily dose (DDD) and DDD costs of antibacterial drugs\u00a0in Germany, based on the Arzneiverordnungsreport (AVR, Drug description report) between 1985 and 2022. Based on prescription rates in 2022, we selected the TOP15 and TOP5. For a more in-depth analysis, we analyzed data from the wissenschaftliches Institut der AOK (WidO, scientific institute of the AOK). The number of prescriptions increased between 1985 and 2013, but since 2014, there has been a declining trend with a noticeable COVID-related dip. Over the years, a shift in drug classes occurred. Once very popular drugs like penicillins and tetracyclines are no longer as important. Conversely, aminopenicillins and cephalosporins have become more relevant. Particularly, the TOP5 drugs have seen an increasing proportion. DDD costs have decreased in most substance classes over time. There is a strong association between decreasing costs and rising prescriptions. Falling costs have a stronger immediate impact on prescriptions that rising costs. When costs are very low, drugs might be prescribed excessively. Supply bottlenecks can also result. The main prescribers are mainly in primary care. Their share of prescription has changed little over the years, but is decreasing regarding total consumption. In comparison to other European countries, Germany ranks in the lower third regarding prescriptions. In most countries, the COVID pandemic has led to a reduced prescription of antibacterial drugs. In conclusion, we provided a comprehensive overview of the antibacterial drug market in Germany over the past four decades and identified costs as a major driver of antibacterial drug prescriptions. Increased costs may reduce uncritical prescription of antibacterial drugs, development of bacterial resistance, supply shortages and occurrence of adverse effects.<\/jats:p>","DOI":"10.1007\/s00210-024-03171-y","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T10:03:15Z","timestamp":1717668195000},"page":"8785-8801","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Costs are a major driver of antibacterial drug prescriptions in Germany: market\u00a0analysis from 1985 to 2022"],"prefix":"10.1007","volume":"397","author":[{"given":"Lilly Josephine","family":"Bindel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"key":"3171_CR1","unstructured":"AOK (2023) Gesetz zur Neuordnung des Arzneimittelmarktes in der gesetzlichen Krankenversicherung \/ Arzneimittelmarktneuordnungsgesetz (AMNOG).\u00a0https:\/\/www.aok.de\/pp\/reform\/amnog\/. Accessed 12 Dec 2023"},{"key":"3171_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1179\/joc.1999.11.Supplement-2.35","volume":"11","author":"F Baquero","year":"1999","unstructured":"Baquero F (1999) Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting Macrolide Consumption? J Chemother 11:35\u201343. https:\/\/doi.org\/10.1179\/joc.1999.11.Supplement-2.35","journal-title":"J Chemother"},{"key":"3171_CR3","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3238\/arztebl.2016.0454","volume":"113","author":"J B\u00e4tzing-Feigenbaum","year":"2016","unstructured":"B\u00e4tzing-Feigenbaum J, Schulz M, Schulz M, Hering R, Kern WV (2016) Antibiotikaverordnung in Der Ambulanten Versorgung Eine bev\u00f6lkerungsbezogene Untersuchung in Deutschland Zum Regionalen, altersgruppenbezogenen Verbrauch Von Cephalosporinen Und Fluorchinolonen. Deutsches \u00c4rzteblatt International 113:454\u2013459. https:\/\/doi.org\/10.3238\/arztebl.2016.0454","journal-title":"Deutsches \u00c4rzteblatt International"},{"key":"3171_CR4","unstructured":"BfArM (Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte Deutschland) (2023) Informationen des BfArM zur eingeschr\u00e4nkten Verf\u00fcgbarkeit von Antibiotika - insbesondere f\u00fcr Kinder (Stand: 09.11.2023).\u00a0https:\/\/www.bfarm.de\/DE\/Arzneimittel\/Arzneimittelinformationen\/Lieferengpaesse\/Archiv\/antibiotika-archiv.html. Accessed 2 May 2024"},{"key":"3171_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.cmi.2019.06.007","volume":"26","author":"B Bluemel","year":"2020","unstructured":"Bluemel B, Goelz H, Goldmann B, Gr\u00fcger J, Hamel H, Loley K, Ludolph T, Meyer J, Miehlke S, Mohr A, T\u00fcffers K, Usadel H, Wagner S, Wenzel H, Wiemer L, Vorreiter J, Eisele B, Hofreuter D, Glocker E- (2020) Antimicrobial resistance of Helicobacter pylori in Germany, 2015 to 2018. Clin Microbiol Infect 26:235\u2013239. https:\/\/doi.org\/10.1016\/j.cmi.2019.06.007","journal-title":"Clin Microbiol Infect"},{"key":"3171_CR6","doi-asserted-by":"publisher","first-page":"5430","DOI":"10.1128\/AAC.00706-11","volume":"55","author":"J Cadena","year":"2011","unstructured":"Cadena J, Nair S, Henao-Martinez AF, Jorgensen JH, Patterson JE, Sreeramoju PV (2011) Dose of trimethoprim-sulfamethoxazole to treat skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 55:5430\u20135432. https:\/\/doi.org\/10.1128\/AAC.00706-11","journal-title":"Antimicrob Agents Chemother"},{"key":"3171_CR7","first-page":"308","volume":"126","author":"R Cadisch","year":"1996","unstructured":"Cadisch R, Streit E, Hartmann K (1996) Exacerbation of pseudoparalytic myasthenia gravis following azithromycin (zithromax). Schweiz Med Wochenschr 126:308\u2013310","journal-title":"Schweiz Med Wochenschr"},{"key":"3171_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/FBP.0000000000000585","volume":"32","author":"AJM Chaves Filho","year":"2021","unstructured":"Chaves Filho AJM, Mottin M, Soares MV, Juc\u00e1 PM, Andrade CH, Macedo DS (2021) Tetracyclines, a promise for neuropsychiatric disorders: from adjunctive therapy to the discovery of new targets for rational drug design in psychiatry. Behav Pharmacol 32:123\u2013141. https:\/\/doi.org\/10.1097\/FBP.0000000000000585","journal-title":"Behav Pharmacol"},{"key":"3171_CR9","unstructured":"DART2030. Bundesministerium f\u00fcr Gesundheit Deutschland (2023) Deutsche Antibiotika-Resistenzstrategie.\u00a0https:\/\/www.bundesgesundheitsministerium.de\/fileadmin\/Dateien\/3_Downloads\/A\/Antibiotika-Resistenz-Strategie\/DART_2030_bf.pdf. Accessed 20 May 2024"},{"key":"3171_CR10","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1055\/s-2004-831838","volume":"129","author":"K de With","year":"2004","unstructured":"de With K, Schr\u00f6der H, Meyer E, Nink K, Hoffmann S, Steib-Bauert M, K\u00e4mmerer R, Rue\u00df S, Daschner FD, Kern WV (2004) Antibiotikaanwendung in Deutschland Im europ\u00e4ischen Vergleich. Dtsch Med Wochenschr 129:1987\u20131992. https:\/\/doi.org\/10.1055\/s-2004-831838","journal-title":"Dtsch Med Wochenschr"},{"key":"3171_CR11","unstructured":"ECDC (European Centre for Disease Prevention and Control) (2020) Antimicrobial consumption in the EU\/EEA (ESAC-Net) - Annual Epidemiological Report 2020. Stockholm: ECDC.\u00a0https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/ESAC-Net%20AER-2020-Antimicrobial-consumption-in-the-EU-EEA.pdf.\u00a0Accessed 28 May 2024"},{"key":"3171_CR12","unstructured":"ECDC (European Centre for Disease Prevention and Control) (2023a) Antimicrobial consumption in the EU\/EEA (ESAC-Net) - Annual Epidemiological Report 2022. Stockholm: ECDC. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/AER-antimicrobial-consumption.pdf. Accessed 28 May 2024"},{"key":"3171_CR13","unstructured":"ECDC (European Centre for Disease Prevention and Control) (2023b) Antimicrobial resistance in the EU\/EEA (EARS-Net) - Annual Epidemiological Report 2022. Stockholm: ECDC. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/AER-antimicrobial-resistance.pdf. Accessed 28 May 2024"},{"key":"3171_CR14","unstructured":"ECDC (European Centre for Disease Prevention and Control) (2024) Antimicrobial Consumption Dashboard (ESAC-net). https:\/\/qap.ecdc.europa.eu\/public\/extensions\/AMC2_Dashboard\/AMC2_Dashboard.html#eu-consumption-tab. Accessed 12 Apr 2024"},{"key":"3171_CR15","doi-asserted-by":"publisher","unstructured":"Ewig SS, H\u00f6ffken G, Kern WV, Rohde G, Flick H, Krause R, Ott S, Bauer T, Dalhoff K, Gatermann S, Kolditz M, Kr\u00fcger S, Lorenz J, Pletz M, De Roux A, Schaaf B, Schaberg T, Sch\u00fctte H, Welte T (2016) Behandlung Von Erwachsenen Patienten mit ambulant erworbener Pneumonie und Pr\u00e4vention \u2013 Update 2016. Pneumologie 70:151. https:\/\/doi.org\/10.1055\/s-0042-101873","DOI":"10.1055\/s-0042-101873"},{"key":"3171_CR16","unstructured":"Ewig S, Kolditz M, Pletz M, Altiner A, Droemann D, Flick H, Gatermann S, Kr\u00fcger S, Nehls W, Panning M, Rademacher J, Rohde G, Rupp J, Schaaf B, Heppner H, Krause R, Ott S, Welte T, Witzenrath M (2021) S3-Leitlinie Behandlung Von Erwachsenen Patienten mit ambulant erworbener Pneumonie - Update 2021, AWMF-Register-Nr. 020\u2013020. Version 30.04.2021.\u00a0https:\/\/register.awmf.org\/assets\/guidelines\/020-020l_S3_Behandlung-von-erwachsenen-Patienten-mit-ambulant-erworbener-Pneumonie__2021-05.pdf. Accessed 28 May 2024"},{"key":"3171_CR17","doi-asserted-by":"publisher","unstructured":"Fuchs F, Hamprecht A (2019) Results from a prospective in Vitro Study on the Mecillinam (Amdinocillin) susceptibility of Enterobacterales. Antimicrob Agents Chemother 63:1\u20134. https:\/\/doi.org\/10.1128\/aac.02402-18","DOI":"10.1128\/aac.02402-18"},{"key":"3171_CR18","unstructured":"GERMAP 2008. Bundesamt f\u00fcr Verbraucherschutz und Lebensmittelsicherheit, Paul-Ehrlich-Gesellschaft f\u00fcr Chemotherapie e.V. (2008) \u2013 Bericht \u00fcber den Antibiotikaverbrauch und die Verbreitung von Antibiotikaresistenzen in der Human- und Veterin\u00e4rmedizin in Deutschland. Antiinfectives Intelligence. First edition. Rheinbach. https:\/\/www.p-e-g.org\/files\/content\/Ueber%20uns\/GERMAP\/GERMAP-2008.pdf. Accessed 28 May 2024"},{"key":"3171_CR19","unstructured":"GERMAP 2015. Bundesamt f\u00fcr Verbraucherschutz und Lebensmittelsicherheit, Paul-Ehrlich-Gesellschaft f\u00fcr Chemotherapie e.V. (2016)  \u2013 Bericht \u00fcber den Antibiotikaverbrauch und die Verbreitung von Antibiotikaresistenzen in der Human- und Veterin\u00e4rmedizin in Deutschland. Antiinfectives Intelligence. Rheinbach. https:\/\/www.p-e-g.org\/files\/content\/Ueber%20uns\/GERMAP\/GERMAP-2015deutsch.pdf. Accessed 28 May 2024"},{"key":"3171_CR20","doi-asserted-by":"publisher","unstructured":"H\u00f6ffken G, Lorenz L, Kern W, Welte T, Bauer T, Dalhoff K, Dietrich E, Ewig S, Gastmeier P, Grabein B, Halle E, Kolditz M, Marre R, Sitter H (2005) S3\u2009\u2013\u2009Leitlinie zu ambulant erworbener Pneumonie und tiefen Atemwegsinfektionen 2005. Pneumologie 2005;59:e16-e21. Georg Thieme Verlauf KG. Stuttgart, New York. https:\/\/doi.org\/10.1055\/s-2005-870988","DOI":"10.1055\/s-2005-870988"},{"key":"3171_CR21","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1128\/AAC.46.8.2540-2545.2002","volume":"46","author":"JA Karlowsky","year":"2002","unstructured":"Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Sahm DF (2002) Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother 46:2540\u20132545. https:\/\/doi.org\/10.1128\/AAC.46.8.2540-2545.2002","journal-title":"Antimicrob Agents Chemother"},{"key":"3171_CR22","doi-asserted-by":"publisher","unstructured":"Kern WV, Kostev K (2021) Prevalence of and Factors Associated with Antibiotic Prescriptions in Patients with Acute Lower and Upper Respiratory Tract Infections\u2014A Case-Control Study. Antibiotics 10:455. https:\/\/doi.org\/10.3390\/antibiotics10040455","DOI":"10.3390\/antibiotics10040455"},{"key":"3171_CR23","unstructured":"Kniehl E, Naber KG, Patientenvertreter P-W, Selbach FME, Wagenlehner I, Schmiemann FME, Hoyme G, F\u00fcnf-St\u00fcck U, Hummers-Pradier R, Kaase E, Kniehl M, Selbach E, Sester I, Vahlensiek U, Watermann W, D., and, Naber KG (2010) S-3 Leitlinie  Harnwegsinfektionen, Kurzfassung. Version 18. M\u00e4rz 2010. AWMF-Register-Nr. 043\/044. https:\/\/www.urologen-service.de\/fileadmin\/MDB\/PDF\/S3_LL_HWI_Kurzfassung_2010.pdf. Accessed 28 May 2024"},{"issue":"12","key":"3171_CR24","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/S1473-3099(13)70318-9","volume":"13","author":"R Laxminarayan","year":"2013","unstructured":"Laxminarayan R, Duse A, Wattal C, Zaidi AKM, Wertheim HFL, Sumpradit N, Vlieghe E, Hara GL, Gould IM, Goossens H, Greko C, So AD, Bigdeli M, Tomson G, Woodhouse W, Ombaka E, Peralta AQ, Qamar FN, Mir F, Kariuki S, Bhutta ZA, Coates A, Bergstrom R, Wright GD, Brown ED, Cars O (2013) Antibiotic resistance\u2014the need for global solutions. The Lancet Infectious Diseases 13(12):1057\u20131098. https:\/\/doi.org\/10.1016\/S1473-3099(13)70318-9","journal-title":"The Lancet Infectious Diseases"},{"key":"3171_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-662-63825-5","volume-title":"Arzneiverordnungs-Report 2021","author":"W Ludwig","year":"2021","unstructured":"Ludwig W, M\u00fchlbauer M, Seifert R (2021) Arzneiverordnungs-Report 2021. Springer, Berlin, Heidelberg, p 1. https:\/\/doi.org\/10.1007\/978-3-662-63825-5"},{"key":"3171_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-662-66303-5","volume-title":"Arzneiverordnungs-Report 2022","author":"W Ludwig","year":"2023","unstructured":"Ludwig W, M\u00fchlbauer M, Seifert R (2023) Arzneiverordnungs-Report 2022. Springer, Berlin, Heidelberg, p 1. https:\/\/doi.org\/10.1007\/978-3-662-66303-5"},{"key":"3171_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-662-68371-2","volume-title":"Arzneiverordnungs-Report 2023","author":"W Ludwig","year":"2024","unstructured":"Ludwig W, M\u00fchlbauer M, Seifert R (2024) Arzneiverordnungs-Report 2023. Springer, Berlin, Heidelberg, p 1. https:\/\/doi.org\/10.1007\/978-3-662-68371-2"},{"key":"3171_CR28","volume-title":"Arzneiverordnungs-Report 1997 (verf\u00fcgungsbeklagte auflage)","author":"U Schwabe","year":"1997","unstructured":"Schwabe U (1997) Arzneiverordnungs-Report 1997 (verf\u00fcgungsbeklagte auflage). Gustav Fischer, Stuttgart, Jena"},{"key":"3171_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-62168-4","volume-title":"Arzneiverordnungs-Report 2020","author":"U Schwabe","year":"2020","unstructured":"Schwabe U, Ludwig W (2020) Arzneiverordnungs-Report 2020, 1 edn. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/978-3-662-62168-4","edition":"1"},{"key":"3171_CR30","volume-title":"Arzneiverordnungs-Report 1985","author":"U Schwabe","year":"1985","unstructured":"Schwabe U, Paffrath D (1985) Arzneiverordnungs-Report 1985. Fischer, Stuttgart, New York"},{"key":"3171_CR31","volume-title":"Arzneiverordnungs-Report 1986","author":"U Schwabe","year":"1986","unstructured":"Schwabe U, Paffrath D (1986) Arzneiverordnungs-Report 1986. Fischer, Stuttgart, New York"},{"key":"3171_CR32","volume-title":"Arzneiverordnungs-Report 1987","author":"U Schwabe","year":"1987","unstructured":"Schwabe U, Paffrath D (1987) Arzneiverordnungs-Report 1987. Fischer, Stuttgart, New York"},{"key":"3171_CR33","volume-title":"Arzneiverordnungs-Report 1988","author":"U Schwabe","year":"1988","unstructured":"Schwabe U, Paffrath D (1988) Arzneiverordnungs-Report 1988. Fischer, Stuttgart, New York"},{"key":"3171_CR34","volume-title":"Arzneiverordnungs-Report 1991","author":"U Schwabe","year":"1991","unstructured":"Schwabe U, Paffrath D (1991) Arzneiverordnungs-Report 1991. Springer, Berlin, Heidelberg"},{"key":"3171_CR35","volume-title":"Arzneiverordnungs-Report 1992","author":"U Schwabe","year":"1992","unstructured":"Schwabe U, Paffrath D (1992) Arzneiverordnungs-Report 1992. Springer, Berlin, Heidelberg"},{"key":"3171_CR36","volume-title":"Arzneiverordnungs-Report 1993","author":"U Schwabe","year":"1993","unstructured":"Schwabe U, Paffrath D (1993) Arzneiverordnungs-Report 1993. Springer, Berlin, Heidelberg"},{"key":"3171_CR37","volume-title":"Arzneiverordnungs-Report 1994","author":"U Schwabe","year":"1994","unstructured":"Schwabe U, Paffrath D (1994) Arzneiverordnungs-Report 1994. Springer, Berlin, Heidelberg"},{"key":"3171_CR38","volume-title":"Arzneiverordnungs-Report 1995","author":"U Schwabe","year":"1995","unstructured":"Schwabe U, Paffrath D (1995) Arzneiverordnungs-Report 1995. Urban & Fischer"},{"key":"3171_CR39","volume-title":"Arzneiverordnungs-Report 1996","author":"U Schwabe","year":"1996","unstructured":"Schwabe U, Paffrath D (1996) Arzneiverordnungs-Report 1996. Springer, Berlin, Heidelberg"},{"key":"3171_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-58436-7","volume-title":"Arzneiverordnungs-Report 1998","author":"U Schwabe","year":"1998","unstructured":"Schwabe U, Paffrath D (1998) Arzneiverordnungs-Report 1998, 1 edn. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/978-3-642-58436-7","edition":"1"},{"key":"3171_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-57215-9","volume-title":"Arzneiverordnungs-Report 1999","author":"U Schwabe","year":"1999","unstructured":"Schwabe U, Paffrath D (1999) Arzneiverordnungs-Report 1999, 1 edn. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/978-3-642-57215-9","edition":"1"},{"key":"3171_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-56832-9","volume-title":"Arzneiverordnungs-Report 2000","author":"U Schwabe","year":"2000","unstructured":"Schwabe U, Paffrath D (2000) Arzneiverordnungs-Report 2000, 1 edn. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/978-3-642-56832-9","edition":"1"},{"key":"3171_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-56434-5","volume-title":"Arzneiverordnungs-Report 2001","author":"U Schwabe","year":"2001","unstructured":"Schwabe U, Paffrath D (2001) Arzneiverordnungs-Report 2001, 1 edn. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/978-3-642-56434-5","edition":"1"},{"key":"3171_CR44","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-11173-4","volume-title":"Arzneiverordnungs-Report 2002","author":"U Schwabe","year":"2002","unstructured":"Schwabe U, Paffrath D (2002) Arzneiverordnungs-Report 2002, 1 edn. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/978-3-662-11173-4","edition":"1"},{"key":"3171_CR45","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-18512-0","volume-title":"Arzneiverordnungs-Report 2003","author":"U Schwabe","year":"2003","unstructured":"Schwabe U, Paffrath D (2003) Arzneiverordnungs-Report 2003, 1 edn. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/978-3-642-18512-0","edition":"1"},{"key":"3171_CR46","doi-asserted-by":"publisher","unstructured":"Schwabe U, Paffrath D (2004) Arzneiverordnungs-Report 2004. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-642-18513-7","DOI":"10.1007\/978-3-642-18513-7"},{"key":"3171_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/3-540-30505-X","volume-title":"Arzneiverordnungs-Report 2005","author":"U Schwabe","year":"2006","unstructured":"Schwabe U, Paffrath D (2006) Arzneiverordnungs-Report 2005. Springer, Berlin, Heidelberg, p 1. https:\/\/doi.org\/10.1007\/3-540-30505-X"},{"key":"3171_CR48","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-34370-7","volume-title":"Arzneiverordnungs-Report 2006","author":"U Schwabe","year":"2007","unstructured":"Schwabe U, Paffrath D (2007) Arzneiverordnungs-Report 2006, 1 edn. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/978-3-540-34370-7","edition":"1"},{"key":"3171_CR49","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-72548-0","volume-title":"Arzneiverordnungs-Report 2007","author":"U Schwabe","year":"2008","unstructured":"Schwabe U, Paffrath D (2008) Arzneiverordnungs-Report 2007, 1 edn. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/978-3-540-72548-0","edition":"1"},{"key":"3171_CR50","doi-asserted-by":"publisher","unstructured":"Schwabe U, Paffrath D (2010a) Arzneiverordnungs-Report 2008. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-540-69219-5","DOI":"10.1007\/978-3-540-69219-5"},{"key":"3171_CR51","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-01080-4","volume-title":"Arzneiverordnungs-Report 2009","author":"U Schwabe","year":"2010","unstructured":"Schwabe U, Paffrath D (2010b) Arzneiverordnungs-Report 2009, 1 edn. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/978-3-642-01080-4","edition":"1"},{"key":"3171_CR52","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-13380-0","volume-title":"Arzneiverordnungs-Report 2010","author":"U Schwabe","year":"2011","unstructured":"Schwabe U, Paffrath D (2011a) Arzneiverordnungs-Report 2010, 1 edn. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/978-3-642-13380-0","edition":"1"},{"key":"3171_CR53","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-21992-4","volume-title":"Arzneiverordnungs-Report 2011","author":"U Schwabe","year":"2011","unstructured":"Schwabe U, Paffrath D (2011b) Arzneiverordnungs-Report 2011, 1 edn. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/978-3-642-21992-4","edition":"1"},{"key":"3171_CR54","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-29242-2","volume-title":"Arzneiverordnungs-Report 2012","author":"U Schwabe","year":"2012","unstructured":"Schwabe U, Paffrath D (2012) Arzneiverordnungs-Report 2012, 1 edn. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/978-3-642-29242-2","edition":"1"},{"key":"3171_CR55","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-37124-0","volume-title":"Arzneiverordnungs-Report 2013","author":"U Schwabe","year":"2013","unstructured":"Schwabe U, Paffrath D (2013) Arzneiverordnungs-Report 2013, 1 edn. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/978-3-642-37124-0","edition":"1"},{"key":"3171_CR56","doi-asserted-by":"publisher","unstructured":"Schwabe U, Paffrath D (2014) Arzneiverordnungs-Report 2014. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-662-43487-1","DOI":"10.1007\/978-3-662-43487-1"},{"key":"3171_CR57","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-47186-9","volume-title":"Arzneiverordnungs-Report 2015","author":"U Schwabe","year":"2015","unstructured":"Schwabe U, Paffrath D (2015) Arzneiverordnungs-Report 2015, 1 edn. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/978-3-662-47186-9","edition":"1"},{"key":"3171_CR58","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-50351-5","volume-title":"Arzneiverordnungs-Report 2016","author":"U Schwabe","year":"2016","unstructured":"Schwabe U, Paffrath D (2016) Arzneiverordnungs-Report 2016, 1 edn. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/978-3-662-50351-5","edition":"1"},{"key":"3171_CR59","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-54630-7","volume-title":"Arzneiverordnungs-Report 2017","author":"U Schwabe","year":"2017","unstructured":"Schwabe U, Paffrath D (2017) Arzneiverordnungs-Report 2017, 1 edn. Springer, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/978-3-662-54630-7","edition":"1"},{"key":"3171_CR60","volume-title":"Arzneiverordnungs-Report 1989","author":"U Schwabe","year":"1989","unstructured":"Schwabe U, Paffrath D, Anlauf M (1989) Arzneiverordnungs-Report 1989. Fischer, Stuttgart, New York"},{"key":"3171_CR61","volume-title":"Arzneiverordnungs-Report 1990","author":"U Schwabe","year":"1990","unstructured":"Schwabe U, Paffrath D, Anlauf M (1990) Arzneiverordnungs-Report 1990. Fischer, Stuttgart, New York"},{"key":"3171_CR62","doi-asserted-by":"publisher","unstructured":"Schwabe U, Paffrath D, Ludwig W, Klauber J (2018) Arzneiverordnungs-Report 2018. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-662-57386-0","DOI":"10.1007\/978-3-662-57386-0"},{"key":"3171_CR63","doi-asserted-by":"publisher","unstructured":"Schwabe U, Paffrath D, Ludwig W, Klauber J (2019) Arzneiverordnungs-Report 2019. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-662-59046-1","DOI":"10.1007\/978-3-662-59046-1"},{"key":"3171_CR64","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1007\/s00210-021-02144-9","volume":"394","author":"R Seifert","year":"2021","unstructured":"Seifert R, Schirmer B (2021) Problems associated with the use of the term antibiotics. Naunyn Schmiedebergs Arch Pharmacol 394:2153\u20132166. https:\/\/doi.org\/10.1007\/s00210-021-02144-9","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"10","key":"3171_CR65","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1002\/pds.5509","volume":"31","author":"I Selke Krulichov\u00e1","year":"2022","unstructured":"Selke Krulichov\u00e1 I, Selke GW, Bennie M et al (2022) Comparison of drug prescribing before and during the COVID-19 pandemic: A cross-national European study. Pharmacoepidemiol Drug Saf 31(10):1046\u20131055. https:\/\/doi.org\/10.1002\/pds.5509","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3171_CR66","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s15010-007-7211-8","volume":"36","author":"J Simk\u00f3","year":"2008","unstructured":"Simk\u00f3 J, Csilek A, Kar\u00e1szi J, Lorincz I (2008) Proarrhythmic potential of antimicrobial agents. Infection 36:194\u2013206. https:\/\/doi.org\/10.1007\/s15010-007-7211-8","journal-title":"Infection"},{"key":"3171_CR67","doi-asserted-by":"publisher","first-page":"2200568","DOI":"10.2807\/1560","volume":"28","author":"C Stoltidis-Claus","year":"2023","unstructured":"Stoltidis-Claus C, Rosenberger KD, Mandraka F, Quante X, Gielen J, Hoffmann D, Wisplinghoff H, Jazmati N (2023) Antimicrobial resistance of clinical Enterobacterales isolates from urine samples, Germany, 2016 to 2021. Euro Surveill 28:2200568. https:\/\/doi.org\/10.2807\/1560","journal-title":"Euro Surveill"},{"key":"3171_CR68","doi-asserted-by":"publisher","unstructured":"Wissenschaftliches Institut der AOK (WIdO) (2020) Der GKV-Arzneimittelmarkt: Klassifikation, Methodik und Ergebnisse 2020. Berlin. https:\/\/doi.org\/10.4126\/FRL01-006421779","DOI":"10.4126\/FRL01-006421779"},{"key":"3171_CR69","doi-asserted-by":"publisher","unstructured":"Wissenschaftliches Institut der AOK (WIdO) (2021) Der GKV-Arzneimittelmarkt: Klassifikation, Methodik und Ergebnisse 2021. Berlin. https:\/\/doi.org\/10.4126\/FRL01-006429816","DOI":"10.4126\/FRL01-006429816"},{"key":"3171_CR70","unstructured":"Wissenschaftliches Institut der AOK (WIdO) (2022) Der GKV-Arzneimittelmarkt: Klassifikation, Methodik und Ergebnisse 2022. Berlin. https:\/\/www.wido.de\/fileadmin\/Dateien\/Dokumente\/Forschung_Projekte\/Arzneimittel\/wido_arz_gkv-arzneimittelmarkt_klassifikation_methodik_ergebnisse_2022.pdf. Accessed 28 May 2024"},{"key":"3171_CR71","unstructured":"Wissenschaftliches Institut der AOK (WIdO) (2023) Der GKV-Arzneimittelmarkt: Klassifikation, Methodik und Ergebnisse 2023. Berlin.\u00a0https:\/\/www.wido.de\/fileadmin\/Dateien\/Dokumente\/Forschung_Projekte\/Arzneimittel\/wido_arz_gkv_arzneimittelmarkt_klassifikation_methodik_ergebnisse_2023.pdf. Accessed 28 May 2024"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03171-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-024-03171-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03171-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T08:41:57Z","timestamp":1730191317000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-024-03171-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,6]]},"references-count":71,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["3171"],"URL":"https:\/\/doi.org\/10.1007\/s00210-024-03171-y","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,6]]},"assertion":[{"value":"22 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This research was conducted according to the guidelines of good scientific practice of the Hannover Medical School () and officially registered as a doctoral thesis project for Lilly Josephine Bindel. The Hannover Medical School follows the guidelines of the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable because publicly available information is used as a data source.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}